New Jersey S3165 requires NJ FamilyCare to reimburse inpatient providers for long-acting injectable antipsychotic drugs at the outpatient rate.

New Jersey S3165 mandates that NJ FamilyCare reimburse inpatient providers for long-acting injectable antipsychotic drugs at the outpatient reimbursement rate. This change aims to better reflect the cost of the drugs and potentially increase access to these medications for individuals with serious mental illness. The bill ensures that the reimbursement for these drugs in inpatient settings is separate from the Diagnostic Related Group reimbursement system and matches the outpatient rate, which is based on the drug's ingredient cost.

New Jersey S3165 requires NJ FamilyCare to reimburse inpatient providers for long-acting injectable antipsychotic drugs at the outpatient rate.

New Jersey S3165 mandates that NJ FamilyCare reimburse inpatient providers for long-acting injectable antipsychotic drugs at the outpatient reimbursement rate. This change aims to better reflect the cost of the drugs and potentially increase access to these medications for individuals with serious mental illness. The bill ensures that the reimbursement for these drugs in inpatient settings is separate from the Diagnostic Related Group reimbursement system and matches the outpatient rate, which is based on the drug's ingredient cost.